These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 22001393)
1. The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia. Crow AR; Suppa SJ; Chen X; Mott PJ; Lazarus AH Blood; 2011 Dec; 118(24):6403-6. PubMed ID: 22001393 [TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Hansen RJ; Balthasar JP Thromb Haemost; 2002 Dec; 88(6):898-9. PubMed ID: 12529736 [TBL] [Abstract][Full Text] [Related]
3. Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia. Smith B; Christodoulou L; Clargo A; Eddleston A; Greenslade K; Lightwood D; Shock A; Tyson K; Brennan FR Int Immunopharmacol; 2019 Jan; 66():362-365. PubMed ID: 30529500 [TBL] [Abstract][Full Text] [Related]
5. Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP? Crow AR; Song S; Suppa SJ; Ma S; Reilly MP; Andre P; McKenzie SE; Lazarus AH Blood; 2011 Jan; 117(3):971-4. PubMed ID: 21045192 [TBL] [Abstract][Full Text] [Related]
6. Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway. Crow AR; Yu H; Han D; Lazarus AH PLoS One; 2013; 8(8):e71882. PubMed ID: 23940791 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. Hansen RJ; Balthasar JP J Pharm Sci; 2003 Jun; 92(6):1206-15. PubMed ID: 12761810 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Song S; Crow AR; Freedman J; Lazarus AH Blood; 2003 May; 101(9):3708-13. PubMed ID: 12506021 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Song S; Crow AR; Siragam V; Freedman J; Lazarus AH Blood; 2005 Feb; 105(4):1546-8. PubMed ID: 15479722 [TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. Garg A; Balthasar JP J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457 [TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory activity of CD44 antibodies in murine immune thrombocytopenia is mediated by Fcγ receptor inhibition. Norris PAA; Kaur G; Khan R; Zhu G; Ni H; Lazarus AH Blood; 2021 Apr; 137(15):2114-2124. PubMed ID: 33662988 [TBL] [Abstract][Full Text] [Related]
12. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. Li N; Zhao M; Hilario-Vargas J; Prisayanh P; Warren S; Diaz LA; Roopenian DC; Liu Z J Clin Invest; 2005 Dec; 115(12):3440-50. PubMed ID: 16284651 [TBL] [Abstract][Full Text] [Related]
13. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Chen P; Li C; Lang S; Zhu G; Reheman A; Spring CM; Freedman J; Ni H Blood; 2010 Nov; 116(18):3660-8. PubMed ID: 20647570 [TBL] [Abstract][Full Text] [Related]
14. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. Tam SH; McCarthy SG; Brosnan K; Goldberg KM; Scallon BJ MAbs; 2013; 5(3):397-405. PubMed ID: 23549129 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Teeling JL; Jansen-Hendriks T; Kuijpers TW; de Haas M; van de Winkel JG; Hack CE; Bleeker WK Blood; 2001 Aug; 98(4):1095-9. PubMed ID: 11493456 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Jin F; Balthasar JP Hum Immunol; 2005 Apr; 66(4):403-10. PubMed ID: 15866704 [TBL] [Abstract][Full Text] [Related]
17. GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out. Lewis BJB; Leontyev D; Neschadim A; Blacquiere M; Branch DR Clin Exp Immunol; 2018 Sep; 193(3):293-301. PubMed ID: 29704458 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. Deng R; Balthasar JP J Pharm Sci; 2007 Jun; 96(6):1625-37. PubMed ID: 17238194 [TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439 [TBL] [Abstract][Full Text] [Related]